Navigation Links
Fate Therapeutics Initiates Phase 2 Clinical Study of ProHema for the Treatment of Hematologic Malignancies
Date:11/27/2012

SAN DIEGO, Nov. 27, 2012 /PRNewswire/ -- Fate Therapeutics, Inc., a biopharmaceutical company engaged in the discovery and development of adult stem cell modulators, announced today the initiation of a randomized, controlled, Phase 2 multi-center study of its investigational hematopoietic stem cell therapy, ProHema, in adult patients undergoing double umbilical cord blood transplantation (dUCBT) for hematologic malignancy.  The advancement of ProHema into later-stage development builds upon positive results from a Phase 1b single-center study, interactions with the U.S. Food and Drug Administration and refinements to the product manufacturing process.  The previously completed Phase 1b study achieved its primary objective of demonstrating safety and tolerability.  The study also established early clinical proof-of-concept – trends of accelerated neutrophil recovery, improved 100-day survival and low rates of graft-versus-host disease were evident, and durable and preferential reconstitution with ProHema occurred in 10 of 12 evaluable patients.  ProHema is produced through a proprietary, two-hour, ex vivo modulation process, which has been shown to significantly activate key biological pathways involved in hematopoietic stem cell homing, proliferation and survival in preclinical models.

"Allogeneic umbilical cord blood transplantation holds great promise as a potentially curative treatment for children and adults with hematologic malignancies and many other life-threatening, non-malignant disorders," said Christian Weyer, M.D., M.A.S., President and Chief Executive Officer of Fate Therapeutics.  "ProHema is being developed with the intent to improve outcomes in patients undergoing cord blood transplantation by facilitating both accelerated engraftment and durable reconstitution using a simple, point-of-care, ex vivo modulation process. The initiation of Phase 2 marks an important milestone for the company and bri
'/>"/>

SOURCE Fate Therapeutics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Epizyme Publishes Current Review on Targeting Protein Methyltransferases for Personalized Cancer Therapeutics
2. MabVax Therapeutics Closes $5.25 Million Financing with Numoda Capital Innovations, Burrill Capital Fund IV, and RTP Venture Fund
3. Cystic Fibrosis Foundation Therapeutics Announces $58 Million CF Drug Discovery Agreement with Pfizer
4. Echo Therapeutics Hires Daniel Sunday as Vice President of Manufacturing and Global Supply Chain
5. Caliber and ImmunGene Launch Valor Biotherapeutics, a Joint Venture to Develop Antibody-Interferon Fusion Therapeutics to Treat Cancers
6. Echo Therapeutics Chosen to Present at the 12th Annual Diabetes Technology Meeting
7. Immunomic Therapeutics Begins Phase I Japanese Red Cedar JRC-LAMP-Vax Vaccine Safety Study
8. Stemline Therapeutics Lead Clinical Candidate SL-401 Induces a Complete Response in a Patient with a Drug-Refractory Plasmacytoid Dendritic Cell Neoplasm
9. Echo Therapeutics Announces Third Quarter 2012 Financial Results
10. Orexigen Therapeutics Reports Financial Results for the Third Quarter Ended September 30, 2012
11. Particle Sciences Develops Novel Ocular Formulation for Eyeon Therapeutics
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... 11, 2014 Research and Markets  has ... Market 2014-2018" report to their offering. ... needle is a hollow needle commonly used with a ... to extract fluids from it. A hypodermic needle is ... substances that cannot be ingested. Hypodermic needles are broadly ...
(Date:7/11/2014)... MELBOURNE, Australia , July 11, 2014  Australian ... today announced that it has raised A$19.3 million via ... Europe , the U.S., ... and A$3 million from a share purchase plan (SPP) ... A$16.3 million will be made in two tranches. ...
(Date:7/11/2014)... New York , July 11, 2014 ... by Transparency Market Research "Endoscopy Devices Market (Endoscopes, Endoscopic ... Size, Share, Growth, Trends and Forecast, 2013-2019" the global ... in 2012 and is expected to grow at a ... an estimated value of USD 36.9 billion in 2019. ...
Breaking Medicine Technology:Global Hypodermic Needles Market 2014-2018: Key Vendors are Becton, Dickinson and Co, Covidien, Retractable Technologies and Terumo Corp. 2Global Hypodermic Needles Market 2014-2018: Key Vendors are Becton, Dickinson and Co, Covidien, Retractable Technologies and Terumo Corp. 3Phosphagenics' A$19.3 million Capital Raising 2Phosphagenics' A$19.3 million Capital Raising 3Global Endoscopy Devices Market is Expected to Reach USD 36.9 Billion by 2019: Transparency Market Research 2Global Endoscopy Devices Market is Expected to Reach USD 36.9 Billion by 2019: Transparency Market Research 3Global Endoscopy Devices Market is Expected to Reach USD 36.9 Billion by 2019: Transparency Market Research 4Global Endoscopy Devices Market is Expected to Reach USD 36.9 Billion by 2019: Transparency Market Research 5Global Endoscopy Devices Market is Expected to Reach USD 36.9 Billion by 2019: Transparency Market Research 6
... A. Grant, MD,Retina Macular Care, presented the ... that was designed to evaluate the adjuvant,use ... Lucentis(R),(ranibizumab) treatment of choroidal neovascularization secondary to,age-related ... presentation at,the 2008 Annual Meeting of the ...
... C Therapies Provides ... Clinical Practice, MILAN, Italy, April 26 Final ... study comparing the,leading therapies for chronic hepatitis C, were ... Association for the Study of the Liver,(EASL), providing important ...
Cached Medicine Technology:Dr. Calvin Grant Presents Results from Xibrom(TM) Combination Therapy with Lucentis(R) at the 2008 Annual Meeting of the Association for Research in Vision and Ophthalmology (ARVO) 2Dr. Calvin Grant Presents Results from Xibrom(TM) Combination Therapy with Lucentis(R) at the 2008 Annual Meeting of the Association for Research in Vision and Ophthalmology (ARVO) 3Dr. Calvin Grant Presents Results from Xibrom(TM) Combination Therapy with Lucentis(R) at the 2008 Annual Meeting of the Association for Research in Vision and Ophthalmology (ARVO) 4Final Results of Ideal Study Presented at Annual Meeting of the European Association for the Study of the Liver (EASL) 2Final Results of Ideal Study Presented at Annual Meeting of the European Association for the Study of the Liver (EASL) 3Final Results of Ideal Study Presented at Annual Meeting of the European Association for the Study of the Liver (EASL) 4Final Results of Ideal Study Presented at Annual Meeting of the European Association for the Study of the Liver (EASL) 5Final Results of Ideal Study Presented at Annual Meeting of the European Association for the Study of the Liver (EASL) 6Final Results of Ideal Study Presented at Annual Meeting of the European Association for the Study of the Liver (EASL) 7Final Results of Ideal Study Presented at Annual Meeting of the European Association for the Study of the Liver (EASL) 8Final Results of Ideal Study Presented at Annual Meeting of the European Association for the Study of the Liver (EASL) 9Final Results of Ideal Study Presented at Annual Meeting of the European Association for the Study of the Liver (EASL) 10
(Date:7/11/2014)... London, UK (PRWEB) July 11, 2014 ... segment of the in-vitro diagnostics industry, which is expected ... next ten years. The sector owes its growth to ... threat to people’s health worldwide and a major factor ... diagnostic technologies, threat of bio-terrorism, and a broader availability ...
(Date:7/11/2014)... Utilizing the Keller Funnel, Quatela Center for ... a record number of complication-free breast augmentations. Far ... procedures without the occurrence of a capsular contraction. ... country for his expertise with the breast augmentation procedure. ... foundation for numerous studies and research. Most recently, ...
(Date:7/11/2014)... July 11, 2014 Ticket Down is ... Concord Pavilion . When it comes to the summer concert ... The 37-year-old Georgia native is one of the biggest names in ... business. Bryan is currently out on his “That’s My Kind of ... stops the tour will be making through the rest of the ...
(Date:7/11/2014)... July 11, 2014 Biostimulants are widely ... in turf and ornamentals. These also help turf and ... length of roots. Turf, ornamentals, and flowers appear healthy ... this usage has increased from the last few years. ... and ornamentals is Europe, with around 40% share in ...
(Date:7/11/2014)... kind has found that organic foods and crops ... counterparts, including more antioxidants and fewer, less frequent ... unprecedented 343 peer-reviewed publications comparing the nutritional quality ... including fruits, vegetables, and grains. The study team ... organic and non-organic foods. , "Science marches ...
Breaking Medicine News(10 mins):Health News:World Virology and Bacteriology Testing Sector Discussed in Comprehensive VPG Research Report Published at MarketPublishers.com 2Health News:World Virology and Bacteriology Testing Sector Discussed in Comprehensive VPG Research Report Published at MarketPublishers.com 3Health News:Rochester Surgeon Hits Milestone with Keller Funnel 2Health News:Luke Bryan Ticket Prices Slashed at Concord Pavilion 2Health News:Luke Bryan Ticket Prices Slashed at Concord Pavilion 3Health News:Biostimulants Market in Turf and Ornamentals is Expected to Reach $ 3.8 Billion by 2018 - New Report by MicroMarket Monitor 2Health News:Biostimulants Market in Turf and Ornamentals is Expected to Reach $ 3.8 Billion by 2018 - New Report by MicroMarket Monitor 3Health News:Major study documents nutritional and food safety benefits of organic farming 2Health News:Major study documents nutritional and food safety benefits of organic farming 3
... Kathleen Doheny HealthDay Reporter , THURSDAY, Oct. 7 ... cancer who have dense breasts may be at higher risk ... breast, a new study indicates. "The risk appears to ... that originally had the cancer," said Laurel A. Habel, a ...
... (Oct. 7, 2010)In 2006, Dr. Shimya Yaminaka of Kyoto ... medicine research world on fire when he successfully transformed ... behave like embryonic stem cells. Embryonic stem cells, the ... the ability to differentiate into any type of tissue. ...
... which participants are randomly assigned to different treatments by ... correctly, it,s widely accepted by the research community that ... But researchers at the University of Michigan ... medical devices to patients by investigating the impact of ...
... HealthDay Reporter , WEDNESDAY, Oct. 6 (HealthDay News) ... be taken with the blood thinner Plavix, a new ... medications, called PPIs, might interfere with the ability of ... reassuring data that there is not any clinically significant ...
... perhaps more than anyone realizes -- in basic biological ... reducing cancer risks, according to University of Oregon researchers. ... zebrafish, scientists in the UO Institute of Molecular Biology ... in the sterile environment of its eggshell through the ...
... friends and family members of mood history and symptoms ... research published online by the journal International Psychogeriatrics ... who is highly outgoing and fun-loving and who is ... miss the signs that indicate the person is depressed. ...
Cached Medicine News:Health News:Denser Breasts Raise Odds of Second Breast Cancer, Study Finds 2Health News:Denser Breasts Raise Odds of Second Breast Cancer, Study Finds 3Health News:Colorado researcher discovers mechanism for changing adult cells into stem-like cells 2Health News:U-M receives NIH, FDA grant to study adaptive clinical trial designs 2Health News:Heartburn Drugs, Plavix Seem Safe to Take Together 2Health News:Heartburn Drugs, Plavix Seem Safe to Take Together 3Health News:Gut microbes promote cell turnover by a well-known pathway 2Health News:Patient personality hinders detection of depression 2